<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932291</url>
  </required_header>
  <id_info>
    <org_study_id>CL07-ORY-2001</org_study_id>
    <nct_id>NCT04932291</nct_id>
  </id_info>
  <brief_title>Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population</brief_title>
  <official_title>&quot;A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oryzon Genomics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oryzon Genomics S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult&#xD;
      borderline personality disorder (BPD) population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PORTICO is a double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial&#xD;
      to evaluate the efficacy and safety of vafidemstat in an adult borderline personality&#xD;
      disorder (BPD) population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Clinical Global Impression-Severity focused on Agitation/Aggression (CGI-S A/A)</measure>
    <time_frame>From baseline up to week 14</time_frame>
    <description>Evaluation of the difference on the Clinical Global Impression-Severity focused on Agitation/Aggression (CGI-S A/A) from baseline to specific week, between the active treatment arm and the placebo arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Borderline Personality Disorder Checklist (BPDCL)</measure>
    <time_frame>From baseline up to week 14</time_frame>
    <description>Evaluation of the difference on the Borderline Personality Disorder Checklist (BPDCL), from baseline to specific week, between the active treatment arm and the placebo arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Clinical Global Impression-Severity focused on Agitation/Aggression (CGI-S A/A)</measure>
    <time_frame>Change up to week 14</time_frame>
    <description>Evaluation of the change over time on the CGI-S A/A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Borderline Personality Disorder Checklist (BPDCL)</measure>
    <time_frame>Change up to week 14</time_frame>
    <description>Evaluation of the change over time on the BPDCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Borderline Evaluation of Severity over Time (BEST)</measure>
    <time_frame>Change up to week 14 and from baseline to week 14</time_frame>
    <description>Evaluation of the difference on BEST between the active treatment arm and the placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>Change up to week 14 and from baseline to week 14</time_frame>
    <description>Evaluation of the difference on BDI-II between the active treatment arm and the placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: State-Trait Anger Expression Inventory 2 (STAXI-2)</measure>
    <time_frame>Change up to week 14 and from baseline to week 14</time_frame>
    <description>Evaluation of the difference on STAXI-2 between the active treatment arm and the placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>Change up to week 14 and from baseline to week 14</time_frame>
    <description>Evaluation of the difference on STAI between the active treatment arm and the placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events</measure>
    <time_frame>From baseline to week 14</time_frame>
    <description>Treatment emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Withdrawn patients</measure>
    <time_frame>From baseline to week 14</time_frame>
    <description>Percentage of withdrawn patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints - Columbia-Suicide Severity Rating Scale (C-SSRS).</measure>
    <time_frame>From baseline to week 14</time_frame>
    <description>Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>vafidemstat 1.2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vafidemstat is administered as capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered as capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vafidemstat</intervention_name>
    <description>1.2mg capsule</description>
    <arm_group_label>vafidemstat 1.2mg</arm_group_label>
    <other_name>ORY-2001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal inclusion criteria:&#xD;
&#xD;
          1. Men and women 18-65 years of age.&#xD;
&#xD;
          2. DSM-5 diagnostic criteria for BPD at least 3 months before the Screening visit. The&#xD;
             Mini-International Neuropsychiatric Interview (MINI) will be administered at screening&#xD;
             in order to confirm BPD diagnosis, as well as to confirm subject does not meet other&#xD;
             relevant exclusion criteria.&#xD;
&#xD;
          3. Agitation-Aggression Psychiatric Inventory-Clinician Report (AAPI-CR) Agitation &amp;&#xD;
             Aggression (A/A) subscale score of &gt; 16 (severity x frequency) summed across the four&#xD;
             (4) items comprising the A/A subscale, and the sum of the A/A subscale severity scores&#xD;
             &gt; 6.&#xD;
&#xD;
          4. Outpatient known to the site or investigator and has been treated by the site or&#xD;
             investigator for at least the last 3 months prior to the Screening visit.&#xD;
&#xD;
          5. Stable living environment for &gt; 6 months before the Screening visit.&#xD;
&#xD;
          6. Body mass index (BMI) of at least 18.5 kg/m2, but no more than 35 kg/m2.&#xD;
&#xD;
          7. Willing and able to adhere to the prohibitions, restrictions and requirements&#xD;
             specified in this protocol.&#xD;
&#xD;
          8. Otherwise, healthy, and medically stable based on medical history.&#xD;
&#xD;
          9. Clinical and neurological examinations and laboratory tests, as well as 12-lead ECG&#xD;
             performed during screening that confirms subject is healthy and medically stable.&#xD;
&#xD;
         10. Able to read and write fluently and must have adequate hearing and visual acuity to&#xD;
             complete the required testing outlined in this protocol.&#xD;
&#xD;
         11. Stable in their permitted regimen of background therapy as per drug labeling for&#xD;
             concomitant medications at the Screening visit and they should maintain treatment&#xD;
             throughout the study and not initiate any prohibited medications during the trial.&#xD;
             Subjects should agree to inform their study physician of any medication changes&#xD;
             throughout the trial.&#xD;
&#xD;
         12. Enrolled subjects will need to maintain their pre-screening psychotherapy schedule&#xD;
             throughout the trial duration. That is, subjects receiving psychotherapy will need to&#xD;
             have it started at least 3 months before the Screening visit and remain in&#xD;
             psychotherapy throughout the trial. Subjects not receiving psychotherapy should not&#xD;
             initiate psychotherapy during the trial.&#xD;
&#xD;
         13. Fertile male and female subjects must use highly efficient contraception, from the&#xD;
             Screening visit until 30 days after last dose of the IMP, defined as:&#xD;
&#xD;
             A method with less than 1% failure rate (e.g., permanent sterilization, hormone&#xD;
             implants, hormone injections, some intrauterine devices, or vasectomized partner) OR&#xD;
             The use of two methods of contraception (e.g., one barrier method [condom, diaphragm&#xD;
             or cervical/vault caps] with spermicide and one hormonal contraceptive [e.g., combined&#xD;
             oral contraceptives, patch, vaginal ring, injectable and implants])&#xD;
&#xD;
         14. Female subjects of childbearing potential must have a negative urine pregnancy test at&#xD;
             screening and baseline.&#xD;
&#xD;
         15. Signed informed consent by participant prior to the initiation of any study specific&#xD;
             procedure.&#xD;
&#xD;
        Principal exclusion criteria&#xD;
&#xD;
          1. DSM-5 diagnosis of intellectual disability, autism spectrum disorder, schizophrenia,&#xD;
             schizoaffective disorder, bipolar disorder (or related disorders) or major depressive&#xD;
             disorder (MDD) with psychosis.&#xD;
&#xD;
          2. Current DSM-5 diagnosis of conduct disorder, anorexia nervosa, bulimia nervosa,&#xD;
             binge-eating disorder, oppositional defiant disorder, paranoid personality disorder or&#xD;
             obsessive-compulsive disorder.&#xD;
&#xD;
          3. Current DSM-5 diagnosis of panic disorder or post-traumatic stress disorder (PTSD).&#xD;
             However, subjects with PTSD, generalized anxiety disorder (GAD), social anxiety&#xD;
             disorder (SAD), MDD without psychosis, attention deficit hyperactivity disorder (ADHD)&#xD;
             are eligible if symptoms have been stable for at least 90 days prior to the Screening&#xD;
             visit, these disorders are not the primary focus of treatment, changes in any&#xD;
             treatment for these disorders would not likely be required for the duration of the&#xD;
             study, and in the investigator´s opinion these disorders will not interfere with the&#xD;
             assessment and/or accuracy of the study endpoints.&#xD;
&#xD;
          4. History of moderate or severe substance or alcohol use disorder according to DSM-5,&#xD;
             with the exception of nicotine and caffeine, within 6-months before screening.&#xD;
&#xD;
          5. Use of illicit drugs for at least one week before Screening and subjects unwilling to&#xD;
             abstain from use of these substances during the study.&#xD;
&#xD;
          6. Hospitalization or medication change for any reason, two months prior to the Screening&#xD;
             visit or during the Screening period, that makes the subject medically or mentally&#xD;
             unsuitable for trial participation.&#xD;
&#xD;
          7. Clinically significant, advanced or unstable disease that is likely to result in rapid&#xD;
             deterioration of the subject's condition or affect their safety during the study.&#xD;
&#xD;
          8. Positive results for tuberculosis, Human Immunodeficiency Virus (HIV), Hepatitis C or&#xD;
             Hepatitis B serology obtained at the Screening Visit.&#xD;
&#xD;
          9. Uncontrolled hypo- or hyperthyroidism at Screening Visit, based on laboratory&#xD;
             parameters.&#xD;
&#xD;
         10. Clinically significant infection within the previous 30-days.&#xD;
&#xD;
         11. Chronic drug intake of specific forbidden medication&#xD;
&#xD;
         12. Esketamine in the past 90 days before the Screening visit.&#xD;
&#xD;
         13. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in the past&#xD;
             90 days before the screening visit.&#xD;
&#xD;
         14. Any regular intake of medications acting directly on central nervous system that&#xD;
             investigator considers relevant to the study.&#xD;
&#xD;
         15. Member or immediate family of the study personnel or subordinate to any of the study&#xD;
             personnel.&#xD;
&#xD;
         16. Enrollment in another investigational study or intake of investigational drug within&#xD;
             the previous 3 months.&#xD;
&#xD;
         17. Suicide attempt within the 6-month prior to the Screening visit or significant risk of&#xD;
             suicide.&#xD;
&#xD;
         18. Any condition that in the opinion of the investigator makes the subject unsuitable for&#xD;
             inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ropacki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oryzon Genomics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Ropacki, MD</last_name>
    <phone>+34935151313</phone>
    <email>PORTICO_queries@oryzon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Gimeno, MD</last_name>
    <phone>+34935151313</phone>
    <email>PORTICO_queries@oryzon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Institutional Review Board</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Grant, Dr</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adams Clinical Trials, LLC</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dyanna Domilici, Dr</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Harding Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emil Coccaro, Dr</last_name>
      <phone>+34 9365151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Intermedika</name>
      <address>
        <city>Sofia</city>
        <state>Sofia-Grad</state>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Donchev, Prof.</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Hera EOOD - Psychiatry Office</name>
      <address>
        <city>Sofia</city>
        <state>Sofia-Grad</state>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibila Dimitrova, Dr</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Mladost-M&quot; Ltd, Psychiatr</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hristo Kozhuharov, Dr.</last_name>
      <phone>+34935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik fur Psychiatrie und Psychotherapie, LMU</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Musil, Dr</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Benjamin Franklin - Klinik für Psychiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Roepke, Dr</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Pascual-Mateos, PhD</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Ferrer-Vinardell, PhD</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Pascual-Mateos, PhD</last_name>
      <phone>+34 935151313</phone>
      <email>PORTICO_queries@oryzon.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Borderline personality disorder</keyword>
  <keyword>vafidemstat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

